Safe and effective process for the treatment of psoriasis with a specific Anti-il-23 antibody

MA55149B1Active Publication Date: 2026-08-31JANSSEN BIOTECH INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: MA55149
Authority / Receiving Office: MA · MA
Patent Type: Patents
Current Assignee / Owner
Priority Date: 2019-11-19
Filing Date: 2019-11-19
Publication Date: 2026-08-31
Estimated Expiration: 2039-11-19

Application Information

Patent Timeline

19 Nov 2019

Priority

19 Nov 2019

Application

MA55149

31 Aug 2026

Publication

MA55149B1

IPC: A61K39/395; A61P17/06; C07K16/24

CPC: A61P17/06; A61K45/06; C07K16/244; A61K2039/545; C07K2317/21; C07K2317/76; A61K2039/505; C07K16/241

Inventors: RANDAZZO Bruce; ANGSANA Julianty

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The invention relates to a method for treating psoriasis in a patient, by the administration of a specific anti-IL-23 antibody, for example, guselkumab, in an amount recognized as being clinically safe and effective, the patient obtaining a PASI90, PASI100 or IGA 0 or 1 score such as measured 16, 24, 32, 40 and 48 weeks after the initial treatment, as well as a higher effectiveness than that of a patient treated with the patient.

Need to check novelty before this filing date? Find Prior Art

Explore free tools for quick IP tasks

Patent Information

Abstract